FreeBioList

Catalysts / MBX

MBX Biosciences (MBX) catalysts

Upcoming FDA decisions and readouts we track for MBX Biosciences, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 12 Sep 2026

FreeBioList tracks 1 upcoming catalyst for MBX Biosciences (MBX, listed on Nasdaq). It concerns MBX 4291 (Obesity (long-acting GLP-1/GIP peptide prodrug)).

First on the list: the Phase 1 readout for MBX 4291 (Obesity (long-acting GLP-1/GIP peptide prodrug)), guided by the company to Q4 2026.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker
MBX
Next catalyst
Q4 2026
Type
Phase 1 readout
Listed options
Yes
Company ▾ Drug ▾ Effect / indication Next catalyst ▾ Phase / type ▾ Status ▾ Source Options
MBX Biosciences MBX · Nasdaq MBX 4291 Obesity (long-acting GLP-1/GIP peptide prodrug) Q4 2026
company guidance		 Phase 1 readout Verified 8-K exhibit 99.1 ↗ Yes

Companies working on related conditions

Also due in Q4 2026